Submitted by Automa??o e Estat?stica (sst@bczm.ufrn.br) on 2016-05-31T20:39:36Z
No. of bitstreams: 1
IrisUcellaDeMedeiros_TESE.pdf: 1627038 bytes, checksum: abacbae1a6fa2f0ce88c897b540dedc4 (MD5) / Approved for entry into archive by Arlan Eloi Leite Silva (eloihistoriador@yahoo.com.br) on 2016-06-03T00:28:56Z (GMT) No. of bitstreams: 1
IrisUcellaDeMedeiros_TESE.pdf: 1627038 bytes, checksum: abacbae1a6fa2f0ce88c897b540dedc4 (MD5) / Made available in DSpace on 2016-06-03T00:28:56Z (GMT). No. of bitstreams: 1
IrisUcellaDeMedeiros_TESE.pdf: 1627038 bytes, checksum: abacbae1a6fa2f0ce88c897b540dedc4 (MD5)
Previous issue date: 2015-08-14 / Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico (CNPq) / Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior (CAPES) / Durante as ?ltimas d?cadas t?m sido demonstrado que existe uma rela??o entre a depress?o maior e a ativa??o do sistema imunol?gico. Nociceptina/orfanina FQ (N/OFQ) ? o ligante natural do receptor acoplado ? prote?na Gi chamado NOP, ambos constituem um sistema pept?dico que est? envolvido na regula??o do humor e de respostas inflamat?rias. Considerando essas a??es, a presente tese teve como objetivo investigar as consequ?ncias do bloqueio da sinaliza??o do receptor NOP nos comportamentos doentio e do tipo depressivo induzidos pela administra??o de lipopolissacar?deo (LPS) em camundongos. A administra??o sist?mica de doses de LPS, que n?o causam sepse, induzem altera??es nos comportamentos de camundongos relacionadas com a atividade das citocinas pr?-inflamat?rias fator de necrose tumoral-? (TNF-?) e interleucinas 6 (IL-6) e 1? (IL- 1 ?). Ap?s 2 a 6 h e 24 h da inje??o intraperitoneal, camundongos tratados com LPS apresentam, respectivamente, o comportamento doentio e o comportamento do tipo depressivo. No presente trabalho, a administra??o de LPS (0,8 mg/kg, ip) induziu sinais de doen?a em camundongos Swiss e CD-1, como perda de peso, redu??o transit?ria da temperatura retal e diminui??o da ingest?o de ra??o e ?gua. Al?m disso, nas 24 h ap?s a inje??o de LPS, essas mesmas linhagens de camundongos mostraram aumento no tempo de imobilidade durante os 6 min que foram submetidos ao teste de suspens?o pela cauda (TSC). O tratamento com nortriptilina (30 mg/kg, ip, 60 minutos antes do TSC) reduziu o tempo de imobilidade dos camundongos controle e tratados com LPS, e foi utilizado como antidepressivo padr?o. A administra??o pr?via ao LPS do antagonista do receptor NOP SB-612111 (10 mg/kg, ip), n?o alterou os comportamento doentio e do tipo depressivo induzidos pelatoxina. No entanto, quando injetado 24 h ap?s o tratamento com LPS, SB-612111 (ip, 30 minutos antes do TSC), como tamb?m o antagonista pept?dico do receptor NOP UFP-101 (10 nmol/2ul, icv, 5 min antes do TSC), inverteram significativamente os efeitos da toxina. O protocolo de indu??o do comportamento do tipo depressivo pela administra??o intraperitoneal de LPS tamb?m foi testado em camundongos nocautes para o receptor NOP (NOP(-/-)) e seus respectivos wild types (NOP(+/+)). O tratamento com LPS provocou altera??es significativas, como a redu??o tempor?ria da temperatura retal nos camundongos NOP(-/-) e perda de peso corporal e redu??o no consumo de ra??o e ?gua em ambos os camundongos NOP(+/+) e NOP(-/-). O consumo de ?gua foi significativamente diferente entre os gen?tipos. A inje??o de LPS induziu altera??es transit?rias nas citocinas pr?-inflamat?rias. Nas 6 horas ap?s o tratamento com LPS, os n?veis s?ricos de TNF-? mostraram-se aumentados significativamente nos camundongos NOP (+/+) e NOP (-/-), j? os n?veis de IL-6 mostraram-se significativamente aumentados apenas no soro dos camundongos NOP (+/+). Nas 24 horas ap?s a inje??o de LPS, os n?veis s?ricos das citocinas pr?-inflamat?rias retornaram ? linha de base. O tratamento com LPS provocou efeitos de tipo depressivo nos camundongos NOP (+/+), mas foi ineficaz nos camundongos NOP (-/-). Os dados obtidos nesta tese mostram que o bloqueio farmacol?gico e gen?tico da sinaliza??o mediada pelo receptor NOP n?o previne os comportamentos doentio e do tipo depressivo induzidos por LPS, no entanto revertem o comportamento do tipo depressivo. Em conclus?o, esses resultados evidenciam o envolvimento do sistema pept?dico N/OFQ - receptor NOP na modula??o dos comportamentos relacionados ao humor e ? ativa??o do sistema imunol?gico. / During the last decades, it has been established that there is a relationship between major depression and activation of immune system. Nociceptin/orphanin FQ (N/OFQ) is the natural ligand of a Gi-protein coupled receptor named NOP, both compose the peptidergic system wich is involved in the regulation of mood states and inflammatory responses. Considering these actions, the present thesis aimed to investigate the consequences of blocking NOP signaling in lipopolysaccharide (LPS)-induced sickness and depressive-like behaviors in mice. Systemic administration of LPS doses, that do not cause sepsis in mice, induce changes in their behaviors related with activity of pro-inflammatory cytokines tumor necrosis factor-? (TNF-?) and interleukins 6 (IL-6) and 1? (IL-1 ?). At the time points of 2 to 6 h and 24 h after intraperitoneal injection, mice treated with LPS displayed, respectively, sickness and depressive-like behaviors. In the present work the administration of LPS 0.8 mg/kg (ip) significantly induced sickness signs in Swiss and CD-1 mice, such as weight loss, transient reduction in rectal temperature and decrease of food and water intake. Moreover at 24 h after LPS injection these same mice strains displayed significantly increased immobility time on the tail suspension test (TST) when compared with control mice, this alteration was not related with possible locomotion impairments as verified on the open field test. Treatment with Nortriptyline 30 mg/kg (ip, 60 min prior the TST) reduced the immobility time of control and LPS-treated mice and was used as standard antidepressant. The NOP receptor antagonist SB-612111 (10 mg/kg, ip), 30 min prior LPS, did not modify LPS-induced sickness signs and depressive-like behavior. However, when injected 24 h after LPS treatment, SB-612111 (ip, 30 min prior the TST) as well as the peptidergic NOP receptor antagonist UFP-101 (10 nmol/2?L, icv, 5 min prior the TST) significantly reversed the toxin effects. The protocol of LPS-induced depressive-like states was also tested in NOP receptor knockout mice (NOP(-/-)) and their respective wild types (NOP(+/+)). LPS evoked transient rectal temperature reduction in NOP(-/-) mice and loss of body weight, food and water intake reduction in both NOP(+/+) and NOP(-/-) mice. The consumption of water was significantly different due to the genotype. LPS injection induced transient changes in pro-inflammatory cytokines. At 6 h after LPS injection, serum levels of TNF-? were significantly increased in NOP(+/+) and NOP(-/-) mice, as the IL-6 levels were significantly increased just in NOP(+/+) serum. At 24 h after LPS treatment the pro-inflammatory cytokines had returned to the baseline levels in both genotypes. LPS treatment elicited depressive-like effects in NOP(+/+) but not in NOP(-/-) mice. The data obtained during the execution of this doctoral thesis reveal that pharmacological and genetic blockade of NOP signaling does not affect LPS evoked sickness signs while reversing depressive-like behavior. In conclusion, these results highlight the involvement of the peptidergic system N/OFQ - NOP receptor in the modulation of behaviors related to mood and activation of the immune system.
| Identifer | oai:union.ndltd.org:IBICT/oai:repositorio.ufrn.br:123456789/20585 |
| Date | 14 August 2015 |
| Creators | Medeiros, Iris Ucella de |
| Contributors | 97013390968, http://lattes.cnpq.br/1759328747578795, Silva, Alianda Maira Cornelio da, 01179848683, Duzzioni, Marcelo, 95103201968, http://lattes.cnpq.br/8429216284843951, Pedrosa, Matheus de Freitas Fernandes, 96728647449, http://lattes.cnpq.br/2929963416385218, Rom?o, Pedro Roosevelt Torres, 56981449404, http://lattes.cnpq.br/4298041503249719, Gavioli, Elaine Cristina |
| Publisher | Universidade Federal do Rio Grande do Norte, PROGRAMA DE P?S-GRADUA??O EM DESENVOLVIMENTO E INOVA??O TECNOL?GICA EM MEDICAMENTOS, UFRN, Brasil |
| Source Sets | IBICT Brazilian ETDs |
| Language | Portuguese |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/doctoralThesis |
| Source | reponame:Repositório Institucional da UFRN, instname:Universidade Federal do Rio Grande do Norte, instacron:UFRN |
| Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.0028 seconds